Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

Novo Nordisk

Status and phase

Completed

Phase 4

Conditions

Diabetes

Diabetes Mellitus, Type 2

Treatments

Drug: glicazide

Drug: metformin

Drug: repaglinide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00568984

AGEE-3017

Details and patient eligibility

About

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes

Enrollment

324 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 diabetes for at least 3 months
No previous treatment for diabetes
HbA1c between 7.0-12.0%
Body Mass Index (BMI) between 19.0-40.0 kg/m2

Exclusion criteria

Type 1 diabetes
Known unstable/untreated proliferative retinopathy
Uncontrolled treated/untreated hypertension
Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures